SIREN : 831475819
GD BIOTECH is a French company founded 8 years ago, specialized in the sector Activités spécialisées, scientifiques et techniques diverses. Based in DOUAI (59500), this company of category ETI shows in 2023 a revenue of 3.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | 3 316 822 € | 2 924 289 € | 65 038 € | N/C | 2 520 € | N/C |
| Net income | 469 255 € | 522 127 € | 219 723 € | -132 212 € | -156 332 € | -145 434 € | -112 404 € |
| EBITDA | N/C | 606 765 € | 230 503 € | 23 871 € | -23 809 € | -29 084 € | -43 672 € |
| Net margin | N/C | 15.7% | 7.5% | -203.3% | N/C | -5771.2% | N/C |
In 2024, GD BIOTECH generates positive net income of 469 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
469 255 €
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
0.0%
44.389%
21.8%
In 2024, the debt ratio of GD BIOTECH (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of GD BIOTECH (44.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2023, the repayment capacity of GD BIOTECH (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 144.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
144.374
In 2024, the liquidity ratio of GD BIOTECH (144.37) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2023, the interest coverage of GD BIOTECH (9.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 176 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 165 days. The company must finance 11 days of gap between collections and payments.
0 €
176 j
165 j
0 j
Based on 98 transactions of similar company sales
(all years),
the value of GD BIOTECH is estimated at
2 277 552 €
(range 458 568€ - 3 831 160€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 98 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare GD BIOTECH with other companies in the same sector:
Voir toutes les statistiques du secteur Activités spécialisées, scientifiques et techniques diverses
The revenue of GD BIOTECH in 2023 is 3.3 M€.
Yes, GD BIOTECH generated a net profit of 469 k€ in 2024.
The headquarters of GD BIOTECH is located in DOUAI (59500), in the department Nord.
The tax return of GD BIOTECH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
GD BIOTECH operates in the sector Activités spécialisées, scientifiques et techniques diverses (NAF code 74.90B). See the 'Sector positioning' section above to compare the company with its competitors.